ArticleScientific reports2024

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.

Takashi Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.